New rabies vaccine trial hopes to protect kids and adults
NCT ID NCT04270838
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This study tests a new rabies vaccine called ChAdOx2 RabG in healthy adults (18-45 years) and young children (2-6 years) living in a country where rabies is common. The goal is to see if the vaccine is safe and triggers a strong immune response. Participants receive either the new vaccine or a standard rabies vaccine for comparison.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RABIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IHI Clinical Trial Facility
Bagamoyo, Tanzania
Conditions
Explore the condition pages connected to this study.